Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21

ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW).

The exclusive event will feature Nexalin’s CEO Mark White, who will provide an in-depth overview of the company’s differentiated approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS) technology. White will highlight Nexalin’s expanding body of clinical evidence—including peer-reviewed studies and collaborations with leading institutions such as UC San Diego—while outlining progress across its next-generation product portfolio, including the Gen-3 HALO Clarity headset and integrated Virtual Clinic platform designed to enable scalable, physician-supervised, at-home treatment. With multiple international regulatory clearances in place and U.S. clinical and regulatory initiatives advancing, Nexalin is executing a clear pathway toward global commercialization. The presentation will also detail how Nexalin’s patented technology, real-time AI-enabled patient monitoring, and growing international footprint position the Company to capitalize on the rapidly expanding mental health and neurostimulation markets.

A live question and answer session will follow the presentation.

To register for the free webinar, please visit: https://www.redchip.com/webinar/NXL/87033006926

Questions can be pre-submitted to [e-mail] or online during the live event.

About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, Oman and Israel. Additional information about the Company is available at: https://nexalin.com/.